Multi-specific monoclonal antibody MsMab-2 recognizes IDH1-R132L and IDH2-R172M mutations

Monoclonal Antibodies in Immunodiagnosis and Immunotherapy

Volumn 32, Issue 6, 2013, Pages 377-381

  Ogasawara, Satoshi ^a   Kaneko, Mika Kato ^a   Tsujimoto, Yuta ^a   Liu, Xing ^a   Kato, Yukinari ^a  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2 HYDROXYGLUTARIC ACID; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; MONOCLONAL ANTIBODY; MUTANT PROTEIN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNIZATION; METABOLITE; NEOPLASM; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RAT; TUMOR DIAGNOSIS; WESTERN BLOTTING;

ANIMALS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIBODY SPECIFICITY; BLOTTING, WESTERN; CHO CELLS; CRICETINAE; CRICETULUS; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; ISOCITRATE DEHYDROGENASE; MICE; MUTATION, MISSENSE; NEOPLASMS; RATS;

EID: 84890693842     PISSN: None     EISSN: 21679436     Source Type: Journal    
DOI: 10.1089/mab.2013.0050     Document Type: Article

References (19)

1. Dang L, White DW, Gross S, Bennett BD, Bittinger MA, Driggers EM, Fantin VR, Jang HG, Jin S, Keenan MC, Marks KM, Prins RM, Ward PS, Yen KE, Liau LM, Rabinowitz JD, Cantley LC, Thompson CB, Vander Heiden MG, and Su SM: Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 2009;462:739-744.
2. Jin G, Reitman ZJ, Duncan CG, Spasojevic I, Gooden DM, Rasheed BA, Yang R, Lopez GY, He Y, McLendon RE, Bigner DD, and Yan H: Disruption of wild-type IDH1 suppresses D-2-hydroxyglutarate production in IDH1-mutated gliomas. Cancer Res 2013;73:496-501.
3. Ward PS, Lu C, Cross JR, Abdel-Wahab O, Levine RL, Schwartz GK, and Thompson CB: The potential for isocitrate dehydrogenase mutations to produce 2-hydroxyglutarate depends on allele specificity and subcellular compartmentalization. J Biol Chem 2013;288:3804-3815.
4. Lu C, Ward PS, Kapoor GS, Rohle D, Turcan S, Abdel-Wahab O, Edwards CR, Khanin R, Figueroa ME, Melnick A, Wellen KE, O'Rourke DM, Berger SL, Chan TA, Levine RL, Mellinghoff IK, and Thompson CB: IDH mutation impairs histone demethylation and results in a block to cell differentiation. Nature 2012;483:474-478.
5. Turcan S, Rohle D, Goenka A, Walsh LA, Fang F, Yilmaz E, Campos C, Fabius AW, Lu C, Ward PS, Thompson CB, Kaufman A, Guryanova O, Levine R, Heguy A, Viale A, Morris LG, Huse JT, Mellinghoff IK, and Chan TA: IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012;483:479-483.
6. Rohle D, Popovici-Muller J, Palaskas N, Turcan S, Grommes C, Campos C, Tsoi J, Clark O, Oldrini B, Komisopoulou E, Kunii K, Pedraza A, Schalm S, Silverman L, Miller A, Wang F, Yang H, Chen Y, Kernytsky A, Rosenblum MK, Liu W, Biller SA, Su SM, Brennan CW, Chan TA, Graeber TG, Yen KE, and Mellinghoff IK: An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 2013;340:626-630.
7. Wang F, Travins J, DeLaBarre B, Penard-Lacronique V, Schalm S, Hansen E, Straley K, Kernytsky A, Liu W, Gliser C, Yang H, Gross S, Artin E, Saada V, Mylonas E, Quivoron C, Popovici-Muller J, Saunders JO, Salituro FG, Yan S, Murray S, Wei W, Gao Y, Dang L, Dorsch M, Agresta S, Schenkein DP, Biller SA, Su SM, de Botton S, and Yen KE: Targeted inhibition of mutant IDH2 in leukemia cells induces cellular differentiation. Science 2013;340:622-626.
8. Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, and Bigner DD: IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009;360:765-773.
9. Paschka P, Schlenk RF, Gaidzik VI, Habdank M, Kronke J, Bullinger L, Spath D, Kayser S, Zucknick M, Gotze K, Horst HA, Germing U, Dohner H, and Dohner K: IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication. J Clin Oncol 2010;28:3636-3643.
10. Hartmann C, Meyer J, Balss J, Capper D, Mueller W, Christians A, Felsberg J, Wolter M, Mawrin C, Wick W, Weller M, Herold-Mende C, Unterberg A, Jeuken JW, Wesseling P, Reifenberger G, and von Deimling A: Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta Neuropathol 2009;118:469-474.
11. Kato Y, Jin G, Kuan CT, McLendon RE, Yan H, and Bigner DD: A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation. Biochem Biophys Res Commun 2009;390:547-551.
12. Kato Y, Natsume A, and Kaneko MK: A novel monoclonal antibody GMab-m1 specifically recognizes IDH1- R132G mutation. Biochem Biophys Res Commun 2013;432: 564-567.
13. Kato Y, and Kaneko MK: Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation. Biochem Biophys Res Commun 2013;433:374-378.
14. Kaneko MK, Tsujimoto Y, Hozumi Y, Goto K, and Kato Y: Novel monoclonal antibodies GMab-r1 and LMab-1 specifically recognize IDH1-R132G and IDH1-R132L mutations. Monoclon Antib Immunodiagn Immunother 2013;32:224-228.
15. Kaneko MK, Tian W, Takano S, Suzuki H, Sawa Y, Hozumi Y, Goto K, Yamazaki K, Kitanaka C, and Kato Y: Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation. Biochem Biophys Res Commun 2011; 406:608-613.
16. Kaneko MK, Morita S, Tsujimoto Y, Yanagiya R, Nasu K, Sasaki H, Hozumi Y, Goto K, Natsume A, Watanabe M, Kumabe T, Takano S, and Kato Y: Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations. Biochem Biophys Res Commun 2013;432:40-45.
17. Takano S, Kato Y, Yamamoto T, Kaneko MK, Ishikawa E, Tsujimoto Y, Matsuda M, Nakai K, Yanagiya R, Morita S, Tsuboi K, and Matsumura A: Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors. J Neurooncol 2012;108:361-373.
18. Kaneko M, Ogasawara S, and Kato Y: Establishment of a novel multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations. Tohoku J Exp Med 2013;230:103-109.
19. Liu X, Kato Y, Kaneko MK, Sugawara M, Ogasawara S, Tsujimoto Y, Naganuma Y, Yamakawa M, Tsuchiya T, and Takagi M: Isocitrate dehydrogenase 2 mutation is a frequent event in osteosarcoma detected by a multi-specific monoclonal antibody MsMab-1. Cancer Med in press: DOI: 10.1002/cam4.149.